PIERFRANCO CONTE

Professore di 1^ fascia

University of Padova

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (10)

Mothaffar Rimawi

Professor, Executive Medical Director

Baylor College of Medicine

UNITED STATES

View details

Ippazio Cosimo Antonazzo

Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca

ITALY

View details

Alessandro Dal Maso

Istituto Oncologico Veneto IOV-IRCCS

ITALY

View details

Guy Jerusalem

BELGIUM

View details

Giancarlo Cesana

Professor of Public Health and Hygiene

University of Milano-Bicocca

ITALY

View details

Maria Vittoria Dieci

University of Padova

ITALY

View details

Roberto D'Amico

Full Professor of Biostatistics

University of Modena and Reggio Emilia

ITALY

View details

Federico Piacentini

PROF. ASSOCIATO

University of Modena and Reggio Emilia

ITALY

View details

Dolors Soy Muner

Institut d'Investigacions Biomèdiques August Pi i Sunyer

SPAIN

View details

Marc Buyse

Chief Scientific Officer

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

PIERFRANCO CONTE

Research Interests

Explore related searches

Contact this professor

Articles (13)

Reply to M. Kusumoto et al

Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer

Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine

<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

Novel Nuclear Medicine Imaging Applications in Immuno-Oncology

Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity

Collaborators (10)

Mothaffar Rimawi

Ippazio Cosimo Antonazzo

Alessandro Dal Maso

Guy Jerusalem

Giancarlo Cesana

Maria Vittoria Dieci

Roberto D'Amico

Federico Piacentini

Dolors Soy Muner

Marc Buyse

Make your next move.